Xiaoqing Chen Selected Research

Ilexhainanoside D

10/2019

The combination of Ilexhainanoside D and ilexsaponin A1 reduces liver inflammation and improves intestinal barrier function in mice with high-fat diet-induced non-alcoholic fatty liver disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xiaoqing Chen Research Topics

Disease

48	Neoplasms (Cancer) 06/2024 - 02/2002
36	Breast Neoplasms (Breast Cancer) 01/2024 - 05/2002
22	Inflammation (Inflammations) 01/2024 - 12/2008
16	Infections 04/2023 - 07/2012
12	Uveitis 05/2022 - 10/2015
12	Ovarian Neoplasms (Ovarian Cancer) 01/2017 - 07/2002
7	Atherosclerosis 07/2016 - 08/2011
6	Fibrosis (Cirrhosis) 01/2023 - 01/2014
5	Parkinson Disease (Parkinson's Disease) 05/2024 - 06/2013
5	Carcinogenesis 03/2024 - 03/2008
4	Neoplasm Metastasis (Metastasis) 04/2023 - 01/2022
4	Herpes Simplex 01/2020 - 07/2012
4	Systemic Lupus Erythematosus (Libman-Sacks Disease) 06/2018 - 01/2008
4	Atrial Fibrillation 01/2018 - 01/2014
4	Ovarian Epithelial Carcinoma 02/2016 - 12/2008
3	Squamous Cell Carcinoma of Head and Neck 03/2024 - 01/2020
3	Sepsis (Septicemia) 06/2023 - 01/2013
3	Non-alcoholic Fatty Liver Disease 08/2022 - 02/2018
3	Birth Weight (Birth Weights) 02/2022 - 01/2020
3	Graves Ophthalmopathy 02/2021 - 01/2017
3	Autoimmune Diseases (Autoimmune Disease) 02/2021 - 01/2008
3	Allergic Conjunctivitis (Giant Papillary Conjunctivitis) 09/2020 - 10/2014
3	Spinal Cord Diseases 05/2019 - 07/2011
3	Pathologic Constriction (Stenosis) 01/2019 - 03/2011
3	Lung Injury 08/2015 - 01/2013
3	Ataxia Telangiectasia (Louis Bar Syndrome) 05/2015 - 02/2002
2	Chronic Hepatitis B 02/2024 - 01/2022
2	Cataract (Cataracts) 02/2024 - 01/2022
2	Bronchopulmonary Dysplasia 12/2023 - 01/2020
2	COVID-19 11/2023 - 01/2021
2	Colorectal Neoplasms (Colorectal Cancer) 01/2023 - 02/2021
2	Glioma (Gliomas) 01/2023 - 12/2022
2	Lupus Nephritis 11/2022 - 01/2008
2	Lymphoma (Lymphomas) 11/2022 - 01/2022
2	Dysbiosis 08/2022 - 07/2021
2	Retinal Vasculitis 05/2022 - 04/2021
2	Critical Illness (Critically Ill) 02/2022 - 09/2021
2	Type 2 Diabetes Mellitus (MODY) 01/2022 - 11/2015
2	Hypertrophy 01/2022 - 01/2018
2	Cardiomegaly (Heart Hypertrophy) 01/2022 - 01/2021
2	Ulcerative Colitis 01/2022 - 02/2021
2	Heart Failure 10/2021 - 01/2019
2	Fever (Fevers) 09/2021 - 01/2021
2	Hyperoxia 01/2021 - 08/2019
2	Acute Lung Injury 01/2021 - 02/2014
2	Carcinoma (Carcinomatosis) 01/2021 - 09/2016

Drug/Important Bio-Agent (IBA)

24	Proteins (Proteins, Gene)FDA Link 01/2024 - 07/2005
13	Biomarkers (Surrogate Marker)IBA 01/2024 - 01/2008
13	Estrogen ReceptorsIBA 01/2022 - 09/2009
11	CytokinesIBA 11/2021 - 01/2013
9	MicroRNAs (MicroRNA)IBA 02/2024 - 02/2016
9	Messenger RNA (mRNA)IBA 02/2024 - 09/2002
7	DNA (Deoxyribonucleic Acid)IBA 06/2022 - 05/2010
7	Progesterone Receptors (Progesterone Receptor)IBA 01/2022 - 05/2002
6	Anti-Bacterial Agents (Antibiotics)IBA 02/2023 - 01/2013
5	Interleukin-6 (Interleukin 6)IBA 01/2024 - 01/2014
5	Transcription Factors (Transcription Factor)IBA 04/2023 - 09/2009
5	Antiviral Agents (Antivirals)IBA 12/2022 - 05/2013
5	Hormones (Hormone)IBA 05/2022 - 07/2002
5	Apolipoproteins E (ApoE)IBA 07/2016 - 07/2012
4	EnzymesIBA 01/2024 - 07/2005
4	Retinaldehyde (Retinal)IBA 05/2022 - 12/2019
4	human ERBB2 proteinIBA 01/2022 - 12/2011
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2021 - 01/2014
3	6-methyladenineIBA 03/2024 - 01/2023
3	LipidsIBA 01/2024 - 01/2014
3	p38 Mitogen-Activated Protein KinasesIBA 01/2024 - 07/2004
3	Surface-Active Agents (Surfactants)IBA 01/2024 - 08/2019
3	piperineIBA 12/2023 - 11/2019
3	Interleukin-17 (Interleukin 17)IBA 04/2023 - 11/2018
3	RNA (Ribonucleic Acid)IBA 04/2023 - 11/2022
3	Long Noncoding RNAIBA 04/2023 - 11/2021
3	Cell-Free Nucleic AcidsIBA 11/2022 - 11/2018
3	ChemokinesIBA 01/2022 - 01/2008
3	Toll-Like Receptor 4IBA 01/2020 - 01/2013
3	Interleukin-4 (Interleukin 4)IBA 11/2018 - 01/2014
3	AntioxidantsIBA 11/2015 - 12/2007
3	Doxycycline (Periostat)FDA LinkGeneric 10/2015 - 01/2013
3	ApolipoproteinsIBA 08/2015 - 07/2012
3	Protein Kinases (Protein Kinase)IBA 07/2011 - 02/2002
2	Hepatitis B Surface Antigens (HBsAg)FDA Link 02/2024 - 01/2022
2	Therapeutic UsesIBA 01/2024 - 11/2021
2	Interleukin-10 (Interleukin 10)IBA 01/2024 - 01/2021
2	Neuroprotective AgentsIBA 12/2023 - 11/2019
2	TeaIBA 11/2023 - 05/2013
2	Glucose (Dextrose)FDA LinkGeneric 10/2023 - 06/2017
2	Phosphotransferases (Kinase)IBA 01/2023 - 01/2021
2	InflammasomesIBA 11/2022 - 10/2021
2	CateninsIBA 11/2022 - 01/2022
2	Adenosine Triphosphate (ATP)IBA 06/2022 - 07/2014
2	Reactive Oxygen Species (Oxygen Radicals)IBA 05/2022 - 08/2018
2	Streptozocin (Streptozotocin)FDA Link 01/2022 - 05/2020
2	LigandsIBA 10/2021 - 01/2021
2	Transforming Growth Factor-beta Type I ReceptorIBA 11/2020 - 01/2020
2	Peptides (Polypeptides)IBA 10/2020 - 01/2018

Therapy/Procedure

18	Therapeutics 02/2024 - 01/2015
4	Diskectomy (Discectomy) 01/2019 - 01/2016
3	Immunotherapy 06/2024 - 01/2023
2	Oncolytic Virotherapy 06/2024 - 01/2022
2	Laminectomy 01/2023 - 01/2018